The safety and efficacy study also found that Laquinimod was well-tolerated, with adverse events similar to those seen with placebo, in all the four dosages used in the clinical trial. The trial lasted eight weeks, with four more weeks of follow-up.
Teva reported the results at the 20th United European Gastroenterology (UEG) conference.
Teva Global R&D president and chief scientific officer Michael Hayden said, "Our developmental program for Laquinimod has demonstrated that the immunomodulatory effects of this oral compound stand to apply to multiple autoimmune diseases, and data presented at UEG showed an impressive impact on clinical remission in Crohn’s disease as early as one week of treatment.These data provide a solid rationale for potential future study of Laquinimod in Crohn’s disease.
You comment was recieved and soon will be published.
Thank you for posting your comment, which will be reviewed for publication.
Load more comments